Skip to main content
Fig. 1 | Molecular Medicine

Fig. 1

From: Therapeutic effects of engineered exosome-based miR-25 and miR-181a treatment in spinocerebellar ataxia type 3 mice by silencing ATXN3

Fig. 1

Characterization of engineered exosomes. (A) Longitudinal trial design. (B) Transmission electron micrograph of RVG-Lamp2b Exos (Scale bar = 100 nm). Size distribution and concentration of RVG-Lamp2b Exos measured by nano-flow cytometry. (C) Transmission electron micrograph and size distribution of RVG-Lamp2b Exos after the loading of miR-25. (D) Western blotting analysis was performed on the HEK293 cells transfected with RVG-lamp2b and their released exosomes. The protein makers of Lamp2b, TSG101 and CD9 were evaluated. (E) The miR-25 and miR-181a were significantly overexpressed in RVG-Lamp2b Exos after miRNA loading, in comparison with unloaded control RVG-Lamp2b Exos. Data were normalized to U6 and presented as fold change relative to the control Exos group. ****<0.0001

Back to article page

Molecular Medicine

ISSN: 1528-3658